S Afr Med J. 1997 Oct;87(10 Pt 2):1410-3.
This guideline has been developed in order to recommend the correct and safe usage of isotretinoin (Roaccutane) in the treatment of acne and related conditions. Aspects such as correct dosage related to the patient's weight and the minimal requirement in relation to blood tests and physician visits have been addressed.
Isotretinoin is known to be the treatment of choice for severe acne. Familiarity with the drug has lowered the threshold for its use in lesser degrees of acne, particularly when scarring is occurring and other options outlined in the guideline have failed or are either unsuitable or not tolerated.
Severe acne causes permanent physical damage and frequently equally severe psychological damage. The correct use of isotretinoin increases the chance of complete cure, thus maximising the chance of meeting the patient's expectations.
Studies have shown that the patient may expect the chance of permanent cure to be between 60% and 80% at a dose ranging from 0.5 to 1 mg/kg body weight per day for a period of 16-20 weeks. Recent evidence suggests that a cumulative dose of 120 mg/kg body weight during the course at a daily dose of 0.75 mg/kg body weight or greater may be more important than the duration of treatment.
The National Dermatology Working Group consisting of 11 consultant dermatologists, all with considerable experience in the use of isotretinoin therapy for acne, using the current literature as back-up, reached consensus on the contents of the document. The document was presented to the Congress of the South African Dermatology Society in May 1997. It was subsequently sent to all registered dermatologists in South Africa for comment.
BENEFITS, HARM AND COSTS: Correct use of isotretinoin will often effect cure and at worst considerably improve acne. Side-effects due to hypervitaminosis A, while almost inevitable, are uncomfortable rather than dangerous. The potential for teratogenicity is stressed. Isotretinoin is an extremely expensive drug, but studies have shown that it is cost-effective when compared with prolonged treatment with other modalities in what is usually a chronic condition.
The optimal dosage recommended is a cumulative dose of 120 mg/kg body weight with a daily dose as close to 1 mg/kg body weight as possible. Isotretinoin is used for severe acne, lesser degrees of acne where scarring is seen, and in patients who do not respond to or cannot tolerate other treatment modalities.
This guideline is similar to those recommended by other groups outside South Africa. It has been scrutinised by all the practising dermatologists in the country. It is endorsed by the Medical Association of South Africa.
制定本指南是为了推荐异维A酸(罗可坦)在治疗痤疮及相关病症时的正确和安全用法。已涉及与患者体重相关的正确剂量以及血液检查和医生问诊的最低要求等方面。
异维A酸是重度痤疮的首选治疗药物。对该药物的熟悉程度降低了其在较轻程度痤疮治疗中的使用门槛,特别是在出现瘢痕形成且本指南中概述的其他治疗方案无效、不适用或无法耐受的情况下。
重度痤疮会造成永久性身体损伤,且常常导致同样严重的心理损伤。正确使用异维A酸可增加完全治愈的几率,从而最大程度地满足患者的期望。
研究表明,患者每日按0.5至1毫克/千克体重的剂量服用16 - 20周,有望获得60%至80%的永久治愈几率。近期证据表明,在疗程中每日按0.75毫克/千克体重或更高剂量服用时,累积剂量达到120毫克/千克体重可能比治疗持续时间更为重要。
由11位皮肤科顾问组成的国家皮肤科工作组,他们在使用异维A酸治疗痤疮方面均有丰富经验,以当前文献为依据,就该文件内容达成了共识。该文件于1997年5月提交给南非皮肤病学会大会。随后发送给南非所有注册皮肤科医生征求意见。
益处、危害和成本:正确使用异维A酸通常能实现治愈,最坏的情况也能显著改善痤疮。维生素A过多症引起的副作用虽然几乎不可避免,但令人不适而非危险。强调了致畸可能性。异维A酸是一种极其昂贵的药物,但研究表明,与通常为慢性病的其他治疗方式的长期治疗相比,它具有成本效益。
推荐的最佳剂量是累积剂量达120毫克/千克体重,每日剂量尽可能接近1毫克/千克体重。异维A酸用于重度痤疮、出现瘢痕的较轻程度痤疮以及对其他治疗方式无反应或无法耐受的患者。
本指南与南非以外其他组织推荐的指南类似。它已由该国所有执业皮肤科医生进行审查。得到了南非医学协会的认可。